Moleculin Biotech (MBRX) News Today $1.08 -0.07 (-6.09%) Closing price 04:00 PM EasternExtended Trading$1.09 +0.01 (+0.93%) As of 04:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Moleculin Biotech target adjusted to $8 from $45 at H.C. WainwrightMarch 3 at 11:34 AM | markets.businessinsider.comMoleculin Abstract Accepted for Poster Presentation at the Acute Leukemias XIX (ISALXIX) International SymposiumMarch 3 at 8:30 AM | prnewswire.comMoleculin Biotech (NASDAQ:MBRX) Now Covered by Analysts at StockNews.comFebruary 26, 2025 | americanbankingnews.comMoleculin Biotech announces pricing of $3.5M registered direct offeringFebruary 25, 2025 | markets.businessinsider.comMoleculin Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At The Market Under Nasdaq RulesFebruary 25, 2025 | prnewswire.comMoleculin Biotech (NASDAQ:MBRX) Stock, Short Interest ReportFebruary 14, 2025 | benzinga.comMoleculin Biotech secures $5.8 million from warrant exerciseFebruary 13, 2025 | msn.comWhy Is Blood Cancer Focused Moleculin Biotech Stock Trading More Than 400% On Thursday?February 13, 2025 | benzinga.comMoleculin Announces Exercise of Warrants for $5.8 Million Gross ProceedsFebruary 13, 2025 | prnewswire.comMoleculin Biotech receives positive FDA guidance for acceleration of AML trialFebruary 13, 2025 | markets.businessinsider.comMoleculin Receives Positive FDA Guidance for Acceleration of its Registration-Enabling MIRACLE Trial for R/R Acute Myeloid Leukemia (AML)February 13, 2025 | prnewswire.comMoleculin Biotech downgraded to Hold from Buy at MaximFebruary 13, 2025 | markets.businessinsider.comMoleculin Announces First European Approval for Phase 3 AML TrialFebruary 11, 2025 | msn.comMoleculin Biotech receives first approval in Europe for AML trial recruitingFebruary 11, 2025 | markets.businessinsider.comMoleculin Receives First Country Approval in Europe to Begin Recruiting for the MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal TrialFebruary 11, 2025 | prnewswire.comMoleculin Biotech reaches agreement to amend investor warrantsFebruary 10, 2025 | msn.comMBRX stock touches 52-week low at $1.46 amid sharp yearly declineJanuary 30, 2025 | msn.comMoleculin Participates in Virtual Investor "What This Means" SegmentJanuary 27, 2025 | prnewswire.comMoleculin Biotech (MBRX) Gets a Buy from Roth MKMJanuary 12, 2025 | markets.businessinsider.comMoleculin Biotech Shares Corporate Presentation UpdateJanuary 8, 2025 | tipranks.comMoleculin Highlights Development Progress of Annamycin, Phase 2 Data Outperforms Billion-Dollar Assets in AML, Phase 3 Data Readouts in 2025 & 2026January 8, 2025 | prnewswire.comMoleculin Biotech Releases Corporate Presentation UpdateDecember 19, 2024 | markets.businessinsider.comMoleculin Biotech Inc MBRXDecember 11, 2024 | morningstar.comMoleculin Evaluates Prelim. Activity Of Annamycin In Acute Ara-C, VEN Resistant Myeloid LeukemiaDecember 11, 2024 | markets.businessinsider.comMoleculin Announces Online Publication of Preclinical Data Demonstrating Significant Activity of Annamycin in Venetoclax Resistant AML ModelDecember 11, 2024 | prnewswire.comMoleculin Biotech Advances Annamycin for AML TreatmentNovember 18, 2024 | markets.businessinsider.comMoleculin Biotech announces new findings on AnnamycinNovember 18, 2024 | markets.businessinsider.comNew Findings Show Moleculin's Annamycin Overcomes Resistance to Venetoclax in AMLNovember 18, 2024 | prnewswire.comMoleculin Biotech Unveils New Corporate PresentationNovember 14, 2024 | tipranks.comMoleculin Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial to H2 2025November 14, 2024 | prnewswire.comMoleculin Biotech, Inc. (NASDAQ:MBRX) Q3 2024 Earnings Call TranscriptNovember 12, 2024 | msn.comMoleculin Receives Institutional Review Board Approval for MIRACLE Phase 3 Pivotal Trial of Annamycin in Combination with Cytarabine for the Treatment of R/R Acute Myeloid Leukemia (AML)November 12, 2024 | prnewswire.comMoleculin Biotech, Inc. (MBRX) Q3 2024 Earnings Call TranscriptNovember 11, 2024 | seekingalpha.comMoleculin Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 11, 2024 | prnewswire.comInsights Ahead: Moleculin Biotech's Quarterly EarningsNovember 7, 2024 | benzinga.comMoleculin to Report Third Quarter 2024 Financial Results on November 8, 2024 and Host Conference Call and WebcastNovember 5, 2024 | prnewswire.comMoleculin Appoints Leading Expert in Pancreatic Cancer to its Scientific Advisory Board to Support Development of AnnamycinNovember 4, 2024 | prnewswire.comMoleculin Biotech’s Annual Meeting Decisions and ElectionsOctober 26, 2024 | markets.businessinsider.comMoleculin Biotech Highlights Annamycin’s AML Treatment PotentialOctober 18, 2024 | finance.yahoo.comTranscript from Moleculin's Recent Virtual Acute Myeloid Leukemia KOL Event Now AvailableOctober 17, 2024 | prnewswire.comMoleculin Biotech Inc (MBRX) Q2 2024 Earnings Call Highlights: Pivotal Phase 3 Trial for ...October 11, 2024 | uk.finance.yahoo.comMoleculin to Host Virtual Acute Myeloid Leukemia KOL Event on October 14, 2024October 7, 2024 | prnewswire.comMoleculin to Present at Two Upcoming Investor ConferencesOctober 4, 2024 | prnewswire.comMoleculin Biotech IncSeptember 25, 2024 | money.usnews.comMoleculin Biotech Sees Positive Data From Annamycin StudySeptember 24, 2024 | marketwatch.comMoleculin Biotech Shares Rise 12% After Positive Annamycin DataSeptember 24, 2024 | marketwatch.comMoleculin Announces Positive In Vivo Efficacy Data of Annamycin in Orthotopic and Experimental Lung Metastatic Models of SarcomaSeptember 23, 2024 | prnewswire.comMoleculin Participates in Virtual Investor "What this Means" SegmentSeptember 16, 2024 | prnewswire.comMoleculin Announces First Patients Treated in Phase 2 Clinical Trial of STAT3 Inhibitor in Combination with Radiation for the Treatment of GlioblastomaSeptember 9, 2024 | prnewswire.comMoleculin to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 3, 2024 | prnewswire.com Get Moleculin Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for MBRX and its competitors with MarketBeat's FREE daily newsletter. Email Address MBRX Media Mentions By Week MBRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MBRX News Sentiment▼0.110.70▲Average Medical News Sentiment MBRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MBRX Articles This Week▼82▲MBRX Articles Average Week Get Moleculin Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for MBRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies INAB News Today NNVC News Today COCP News Today LSTA News Today ORGS News Today CGTX News Today SLGL News Today HCWB News Today CARM News Today GLYC News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MBRX) was last updated on 3/4/2025 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | Sponsored77 Hedge Funds Are Betting On This Off-Radar MineralWith surging prices... supply shortages... and growing demand, hedge funds are betting big on potash. In fa...The Tomorrow Investor | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s Victory Could Spark Major Gains for Gold – Don’t Miss Out This "Patriot's Tax Shield" lets you defend your wealth with real, solid gold. Our exclusive, free wealth pr...American Alternative | SponsoredWhy 2026 will be a disaster for many AmericansWall Street Legend: Why stocks are very likely to crash in Trump's 2nd Year Legendary investor Marc Chaikin...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Moleculin Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Moleculin Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
